keyword
https://read.qxmd.com/read/38732259/exploring-the-role-of-apigenin-in-neuroinflammation-insights-and-implications
#1
REVIEW
Karine Charrière, Vincent Schneider, Manon Perrignon-Sommet, Gérard Lizard, Alexandre Benani, Agnès Jacquin-Piques, Anne Vejux
Neuroinflammation, a hallmark of various central nervous system disorders, is often associated with oxidative stress and neuronal or oligodendrocyte cell death. It is therefore very interesting to target neuroinflammation pharmacologically. One therapeutic option is the use of nutraceuticals, particularly apigenin. Apigenin is present in plants: vegetables (parsley, celery, onions), fruits (oranges), herbs (chamomile, thyme, oregano, basil), and some beverages (tea, beer, and wine). This review explores the potential of apigenin as an anti-inflammatory agent across diverse neurological conditions (multiple sclerosis, Parkinson's disease, Alzheimer's disease), cancer, cardiovascular diseases, cognitive and memory disorders, and toxicity related to trace metals and other chemicals...
May 6, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38732190/a-systematic-review-of-semaglutide-s-influence-on-cognitive-function-in-preclinical-animal-models-and-cell-line-studies
#2
REVIEW
Raluca Oana Tipa, Daniela-Gabriela Balan, Mihai-Teodor Georgescu, Luciana Angela Ignat, Ileana Adela Vacaroiu, Dragos Eugen Georgescu, Laura Raducu, Doina Andrada Mihai, Liviu-Vasile Chiperi, Andra-Elena Balcangiu-Stroescu
Since we aim to test new options to find medication for cognitive disorders, we have begun to assess the effect of semaglutide and to conduct a review gathering studies that have attempted this purpose. This systematic review focuses on the cognitive effects of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), in the context of neurological and cognitive impairment. Semaglutide, a synthetic GLP-1 analog, showcased neuroprotective effects beyond metabolic regulation. It mitigated apoptosis and improved cognitive dysfunction in cerebrovascular disease, suggesting broader implications for neurological well-being...
May 2, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38730098/the-influence-of-depression-and-anxiety-on-cognition-in-people-with-multiple-sclerosis-a-cross-sectional-analysis
#3
JOURNAL ARTICLE
David E Freedman, Jiwon Oh, Alex Kiss, Juliana Puopolo, Margaret Wishart, Cecilia Meza, Anthony Feinstein
There are conflicting findings about the relationships between depression, anxiety, and cognitive dysfunction in people with multiple sclerosis (MS), and a paucity of research has examined the cumulative influence on cognition of depression plus anxiety. This study aimed to determine whether elevated symptoms of depression and anxiety alone or in combination are associated with worse cognition in people with MS. In this cross-sectional analysis, people with MS consecutively seen at a tertiary neuropsychiatry clinic completed the Hospital Anxiety and Depression Scale for symptoms of depression (HADS-D) and anxiety (HADS-A), and the Minimal Assessment of Cognitive Function in MS for cognitive indices...
May 11, 2024: Journal of Neurology
https://read.qxmd.com/read/38730097/long-term-clinical-outcomes-in-patients-with-cis-treated-with-interferon-beta-1b-results-from-the-15-year-follow-up-of-the-benefit-trial
#4
JOURNAL ARTICLE
Ludwig Kappos, Gilles Edan, Mark S Freedman, Hans-Peter Hartung, Xavier Montalbán, Frederik Barkhof, Ralf Koelbach, David G MacManus, Eva-Maria Wicklein
Multiple sclerosis (MS) treatment intervention with immunomodulating therapy at early disease stage improves short term clinical outcomes. The objective of this study is to describe the long-term outcomes and healthcare utilization of patients with clinically isolated syndrome (CIS) included in the Betaferon®/Betaseron® in Newly Emerging MS for Initial Treatment (BENEFIT) randomized, parallel group trial. In BENEFIT patients were assigned to "early" IFNB-1b treatment or placebo ("delayed" treatment)...
May 10, 2024: Journal of Neurology
https://read.qxmd.com/read/38729781/metabolic-syndrome-and-the-phenotype-of-multiple-sclerosis
#5
JOURNAL ARTICLE
H Gauthier, M Zedet, A Wahab, S Baldé, B Bapst, C Lafont, A Créange
BACKGROUND: Comorbidities, particularly vascular comorbidities, have been shown to exacerbate the progression of disability in multiple sclerosis (MS). Metabolic syndrome (MetS) is a cluster of conditions including abdominal obesity, insulin resistance, atherogenic dyslipidemia, and vascular dysfunction, which contribute to vascular morbidity and chronic inflammation. OBJECTIVE: To describe the characteristics of MetS in a cohort of MS patients and evaluate its relationship with the MS phenotype...
May 9, 2024: Revue Neurologique
https://read.qxmd.com/read/38728959/suicidal-ideation-in-people-with-multiple-sclerosis-and-its-association-with-coping-self-efficacy
#6
JOURNAL ARTICLE
Pavol Mikula, Vladimira Timkova, Marianna Vitkova, Jarmila Szilasiova, Iveta Nagyova
BACKGROUND: Chronic neurological disease such as multiple sclerosis (MS), is a significant risk factor for psychological distress, which can result in suicidal behaviour. Suicidal ideation (SI) is considered a harbinger of suicide-related mortality. However, so far, little is known about the role of protective factors against SI in MS. OBJECTIVE: This study aims to assess the association between coping self-efficacy and SI when controlled for sociodemographic variables, clinical variables, sleep-related problems, and depression...
May 7, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38725151/intrinsic-and-extrinsic-contributors-to-subregional-thalamic-volume-loss-in-multiple-sclerosis
#7
JOURNAL ARTICLE
Eva A Krijnen, Elsa Salim Karam, Andrew W Russo, Hansol Lee, Florence L Chiang, Menno M Schoonheim, Susie Y Huang, Eric C Klawiter
OBJECTIVE: To evaluate the intrinsic and extrinsic microstructural factors contributing to atrophy within individual thalamic subregions in multiple sclerosis using in vivo high-gradient diffusion MRI. METHODS: In this cross-sectional study, 41 people with multiple sclerosis and 34 age and sex-matched healthy controls underwent 3T MRI with up to 300 mT/m gradients using a multi-shell diffusion protocol consisting of eight b-values and diffusion time of 19 ms...
May 9, 2024: Annals of Clinical and Translational Neurology
https://read.qxmd.com/read/38722789/advancing-neurological-health-insights-into-aging-immunity-and-vascular-dynamics
#8
EDITORIAL
Tongtong Xu, Jing Ye, Lin Gan, Shiyu Deng, Yiyan Guo, Yaohui Tang
This editorial provides an overview of recent advancements in the understanding and treatment of neurological disorders, focusing on aging, immunity, and blood flow, as featured in this special issue. The first section explores the importance of identifying biomarkers of aging and aging-related diseases, such as Alzheimer's Disease, highlighting the emerging role of saliva-based biomarkers and the gut-brain axis in disease diagnosis and management. In the subsequent section, the dysregulated immune systems associated with aging are discussed, emphasizing the intricate landscape of the immune system during aging and its bidirectional relationship with neuroinflammation...
May 7, 2024: Aging and Disease
https://read.qxmd.com/read/38722503/multiple-sclerosis-and-covid-19-a-northern-china-survey
#9
JOURNAL ARTICLE
Qian Guo, Tianwei Wang, Yusen Huang, Fangruyue Wang, Pingping Hao, Le Fang
BACKGROUND: There is insufficient data on severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) infection in Chinese patients with multiple sclerosis (pwMS). This study aims to explore the manifestation of pwMS during the Coronavirus disease 2019 (COVID-19) pandemic and the effect of SARS-CoV-2 infection on the prognosis of MS in northern China. METHODS: In this cross-sectional study, an online self-administered questionnaire and telephone interviews were conducted among pwMS of northern China...
May 9, 2024: Neurological Sciences
https://read.qxmd.com/read/38722375/physiological-aging-and-inflammation-induced-cellular-senescence-may-contribute-to-oligodendroglial-dysfunction-in-ms
#10
JOURNAL ARTICLE
Farina Windener, Laureen Grewing, Christian Thomas, Marie-France Dorion, Marie Otteken, Lara Kular, Maja Jagodic, Jack Antel, Stefanie Albrecht, Tanja Kuhlmann
Aging affects all cell types in the CNS and plays an important role in CNS diseases. However, the underlying molecular mechanisms driving these age-associated changes and their contribution to diseases are only poorly understood. The white matter in the aging brain as well as in diseases, such as Multiple sclerosis is characterized by subtle abnormalities in myelin sheaths and paranodes, suggesting that oligodendrocytes, the myelin-maintaining cells of the CNS, lose the capacity to preserve a proper myelin structure and potentially function in age and certain diseases...
May 9, 2024: Acta Neuropathologica
https://read.qxmd.com/read/38721672/choroid-plexus-imaging-in-multiple-sclerosis-management-a-systematic-review
#11
JOURNAL ARTICLE
Justyna Wołos, Olga Grodzka, Jan Kochanowski, Izabela Domitrz
INTRODUCTION: Multiple sclerosis (MS) is a central nervous system (CNS) disease associated with inflammation, demyelination, and neurodegeneration. It affects more than 2 million people globally, and usually occurs in young adults, three-quarters of whom are women. Importantly, accurate diagnosis and treatment are essential, as this disease can lead to the rapid development of disability. The choroid plexus (CP) is a structure widely known as the main cerebrospinal fluid source. However, it is also involved in immune cell trafficking to the cerebrospinal fluid, which is increased in different neurological disorders, particularly those associated with neuroinflammation...
May 9, 2024: Neurologia i Neurochirurgia Polska
https://read.qxmd.com/read/38721606/gut-microbiota-and-autoimmune-neurologic-disorders-a-two-sample-bidirectional-mendelian-randomization-study
#12
JOURNAL ARTICLE
Mengyuan Zhang, Jie Fang, Chamou Zheng, Qing Lin, Jiawei Zhang
BACKGROUND: Increasing evidence has suggested that alterations in the gut microbiome are correlated with autoimmune neurologic disorders, yet the causal relationship between them has yet to be established. METHODS: From the published genome-wide association study (GWAS) summary statistics, we obtained data on the gut microbiota and three autoimmune neurologic disorders (Multiple Sclerosis, Guillain-Barré Syndrome, and Myasthenia Gravis). We then implemented a two-sample Mendelian Randomization (MR) to determine the causal relationship between the gut microbiota and the diseases...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38721160/neuromyelitis-optica-and-immune-thrombocytopenic-purpura-treated-with-rituximab-in-a-patient-with-combined-neurologic-and-hematologic-disorder-a-case-report
#13
Mary Remilenne E Rebanal-Ricafrente, Ma Luisa Gwenn P Tiongson
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory demyelinating disease of the central nervous system affecting the optic nerves and spinal cord. Immune thrombocytopenia (ITP), on the other hand, is an autoimmune disorder characterized by a platelet count of <100 in the absence of any known condition that could be associated with thrombocytopenia. This case report focuses on a 56-year-old female presenting with the unique coexistence of NMOSD and ITP. A 56-year-old woman of Russian descent had a sudden onset of right eye blindness at the age of 24 and was diagnosed with multiple sclerosis...
April 2024: Curēus
https://read.qxmd.com/read/38719983/discovery-of-a-brain-penetrant-small-molecule-antagonist-targeting-lpa1-receptors-to-reduce-neuroinflammation-and-promote-remyelination-in-multiple-sclerosis
#14
JOURNAL ARTICLE
Michael M Poon, Kym I Lorrain, Karin J Stebbins, Geraldine C Edu, Alexander R Broadhead, Ariana O Lorenzana, Bryanna E Paulson, Christopher S Baccei, Jeffrey R Roppe, Thomas O Schrader, Lino J Valdez, Yifeng Xiong, Austin C Chen, Daniel S Lorrain
Multiple sclerosis (MS) is a chronic neurological disease characterized by inflammatory demyelination that disrupts neuronal transmission resulting in neurodegeneration progressive disability. While current treatments focus on immunosuppression to limit inflammation and further myelin loss, no approved therapies effectively promote remyelination to mitigate the progressive disability associated with chronic demyelination. Lysophosphatidic acid (LPA) is a pro-inflammatory lipid that is upregulated in MS patient plasma and cerebrospinal fluid (CSF)...
May 8, 2024: Scientific Reports
https://read.qxmd.com/read/38719433/active-and-non-active-progression-independent-of-relapse-activity-within-the-first-20-years-of-relapsing-multiple-sclerosis
#15
JOURNAL ARTICLE
Adil Maarouf, Jan Patrick Stellmann, Audrey Rico, Clemence Boutiere, Sarah Demortiere, Pierre Durozard, Wafaa Zaaraoui, Jean-Philippe Ranjeva, Jean Pelletier, Bertrand Audoin
BACKGROUND: Progression independent of relapse activity (PIRA) has been described since the early stage of relapsing multiple sclerosis (RMS). However, little is known about the relation between PIRA and inflammatory activity that is particularly important at this stage of the disease. METHOD: We included 110 patients in a prospective study within 18 months of RMS onset. MRI examinations and clinical visits were scheduled on the same day for months 0, 6, 12, 24, 36, 60, 84, 120, 180 and 240...
May 6, 2024: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/38718817/-infections-and-multiple-sclerosis
#16
JOURNAL ARTICLE
Felicita Heidler, Tobias Bopp, Matthias Schwab, FrankA Hoffmann, Hansjörg Schild, Martina Kannler, Mathias Pletz, Uwe K Zettl
No abstract text is available yet for this article.
May 8, 2024: Fortschritte der Neurologie-Psychiatrie
https://read.qxmd.com/read/38718748/neda-3-achievement-in-early-highly-active-relapsing-remitting-multiple-sclerosis-patients-treated-with-ocrelizumab-or-natalizumab
#17
JOURNAL ARTICLE
Elisabetta Signoriello, Alessio Signori, Giacomo Lus, Giuseppe Romano, Girolama Alessandra Marfia, Doriana Landi, Francesca Napoli, Emanuele D' Amico, Aurora Zanghí, Paola Sofia Di Filippo, Daniele Caliendo, Antonio Carotenuto, Antonio Luca Spiezia, Roberta Fantozzi, Diego Centonze, Matteo Lucchini, Massimiliano Mirabella, Eleonora Cocco, Jessica Frau, Giorgia Teresa Maniscalco, Maria Elena Di Battista, Matteo Foschi, Andrea Surcinelli, Simona Bonavita, Gianmarco Abbadessa, Livia Pasquali, Maria Di Gregorio, Maria Teresa Ferrò, Maria Pia Sormani, Irene Schiavetti
BACKGROUND: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatment-naïve HAMS patients receiving NAT or OCR over three years...
April 6, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38717709/the-shoulders-we-keep-standing-on-remembering-otto-marburg-a-big-brain-in-neurology-and-multiple-sclerosis-at-150
#18
EDITORIAL
Klaus Schmierer, Hans Lassmann
No abstract text is available yet for this article.
May 8, 2024: Acta Neuropathologica
https://read.qxmd.com/read/38717582/aseptic-meningitis-and-fabry-disease
#19
JOURNAL ARTICLE
Camille Montardi, Augustin Gaudemer, Mathieu Zuber, Francis Vuillemet, Jean-François Alexandra, Olivier Lidove, Wladimir Mauhin
OBJECTIVE: Fabry disease is caused by enzymatic defects in alpha-galactosidase A that leads to the accumulation of glycosphingolipids throughout the body, resulting in a multisystemic disorder. The most common neurological manifestations are neuropathic pain, autonomic nervous system dysfunction and strokes, but some rarer neurological manifestations exist. Among these, aseptic meningitis is a possible complication. Our objectives were to measure the prevalence of this complication in a cohort of patients with Fabry disease, and to describe its clinical features...
May 8, 2024: Annals of Clinical and Translational Neurology
https://read.qxmd.com/read/38716751/use-of-the-combination-of-spirometry-arterial-blood-gas-analysis-and-overnight-oximetry-to-predict-the-outcomes-of-patients-affected-by-motor-neuron-disease-the-milan-torin-respiratory-score-mi-to-rs
#20
JOURNAL ARTICLE
Paride Schito, Umberto Manera, Tommaso Russo, George Cremona, Elisa Riboldi, Andrea Tettamanti, Federica Agosta, Angelo Quattrini, Adriano Chiò, Massimo Filippi, Andrea Calvo, Nilo Riva
BACKGROUND AND PURPOSE: The use of multiple tests, including spirometry, arterial blood gas (ABG) analysis and overnight oximetry (OvOx), is highly recommended to monitor the respiratory function of patients with motor neuron disease (MND). In this study, we propose a composite score to simplify the respiratory management of MND patients and better stratify their prognosis. MATERIALS AND METHODS: We screened the clinical charts of 471 non-ventilated MND patients referred to the Neuro-rehabilitation Unit of the San Raffaele Scientific Institute of Milan (January 2001-December 2019), collecting spirometric, ABG and OvOx parameters...
May 8, 2024: European Journal of Neurology
keyword
keyword
91337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.